Experimental cell therapy takes on lupus and other autoimmune diseases

NCT ID NCT07123519

Recruiting now Disease control Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune cells. The main goal is to check if the treatment is safe, while also looking for signs that it might help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YTS109 cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 18 participants, so it's primarily testing safety. The treatment may not work, and there could be serious side effects like immune reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis antiphospholipid syndrome autoimmune disease inclusion body myositis lupus nephritis myositis disease Recurrence Sjogren syndrome systemic lupus erythematosus thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS ANTIPHOSPHOLIPID SYNDROME (APS) INFLAMMATORY MYOPATHY LUPUS NEPHRITIS (LN) SJOGREN'S SYNDROME (SS) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital, China
RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.